



ALLIANCEBERNSTEIN®

HEALTHCARE INVESTING

Focusing on Business,
not Science





The global healthcare industry is facing major challenges today that are also creating big opportunities for investors.

Over the past 20 years, innovation has swept through the healthcare sector. But at the same time, growing pressures relating to policy, demographics and certain unwelcome pricing trends have added uncertainty. We think there is now an inherent tension between **innovation**, **pricing** (the price companies can charge) and **policy** (the overall cost to the system).

Innovation

Many of the scientific realities of today were just dreams two decades ago. Innovation in healthcare is redefining the sector's business dynamics in areas such as:

- + **DNA Sequencing**—In the 1990s, sequencing one human genome cost roughly US\$3 billion and took 15 years. Today it can be done for roughly US\$1,000 dollars in less than an hour. We expect further efficiencies going forward to bring costs down to US\$100 per genome. And the data generated from sequencing DNA will unlock greater insights into how to develop better drugs and diagnostics, allowing earlier intervention with better medicines to greatly improve outcomes.
- + **Robotic Surgery**—Two decades ago, robotic surgery was in its infancy. Today it has been used over six million times cumulatively and one million times in 2018 alone. We believe the further penetration of robotics globally will continue to make the healthcare system more efficient through faster recovery times and lower complication rates.
- + **Virtualization**—Rapid advances in the virtualization of healthcare services mean that patients can now access medical care through their smartphones to enable quicker delivery of care and reduced costs.

Our investment process focuses on global companies with strong business fundamentals. We do not try to predict scientific outcomes.

Many healthcare investors attempt to bet on whether a drug trial will be successful in the hope that, if it is, investors will pay more and the drug company's stock price will rise. This is a flawed strategy, in our view. Even the scientists working on these trials, who may have devoted decades of their professional lives to these drugs, cannot predict the results.

As investors, we do not have any more reliable insight into a drug's likely effectiveness than the company. When we evaluate pharmaceutical companies, we invest in those that already have a profitable and proven product line-up as opposed to companies that the market thinks might have a promising future pipeline.



“We don’t believe you can consistently predict scientific outcomes and deliver a repeatable investment process over the long term, so we focus on the business.” Vinay Thapar, Portfolio Manager

Pricing and Policy

Concerns and key challenges

- + Some healthcare companies have relied too much on price rises; this is a very different model from other sectors. Technology companies cannot raise the price of one of their older phone or television models. But this often happens in the pharmaceuticals market. In our view, this is an unsustainable business model that needs to change to better align pricing with the value of products and services.
- + Twenty years ago, chemotherapy cost US\$200 per month, there were awful side effects and it might have extended the patient’s life by a few weeks. Now, the performance of the therapy has increased dramatically to the point where in many cases, cancer patients can be cured. However, the treatment is much more expensive and can cost US\$100,000.
- + The US consumer has become more responsible for bearing the cost of their treatment post Affordable Care Act/Obamacare. When consumers have to pay the first US\$5,000, they are more aware and careful about what they are paying for.
- + However, overall, there is a secular, long-term growth trend in global healthcare. In particular, emerging markets are fuelling growth as these countries rise up the wealth curve and invest more in healthcare, either through policy or from individuals who are spending a larger proportion of their growing wealth on healthcare. Companies that can deliver value-enhancing products and save costs in the system should benefit from huge growth opportunities, in our view.

Business Fundamentals

We look for businesses whose products benefit the patient, create efficiencies in the overall healthcare system and result in improving profitability for the company.

Taking these three forces into consideration, we seek to evaluate a healthcare business without trying to predict the outcome of clinical drug trials. In our view, innovative healthcare companies that are positioned for long-term success amid pricing pressures and shifting policy sands should demonstrate the following attributes:

- + High or improving returns on invested capital (ROIC)
- + Strong reinvestment rates
- + Healthy balance sheets
- + Durable competitive advantages

Investing effectively in healthcare stocks requires a unique set of skills. It’s not about scientific insight. By applying a disciplined investment process that integrates the diverse factors that affect healthcare businesses, investors can access sources of strong return potential that can invigorate an equity portfolio for the long term.



Source AllianceBernstein, as of 28 February 2022.

Investment involves risk. The information contained here reflects the views of AllianceBernstein L.P. or its affiliates and sources it believes are reliable as of the date of this publication. AllianceBernstein L.P. makes no representations or warranties concerning the accuracy of any data. There is no guarantee that any projection, forecast or opinion in this material will be realized. Past performance does not guarantee future results. The views expressed here may change at any time after the date of this publication. This document is for informational purposes only and does not constitute investment advice. AllianceBernstein L.P. does not provide tax, legal or accounting advice. It does not take an investor's personal investment objectives or financial situation into account; investors should discuss their individual circumstances with appropriate professionals before making any decisions. This information should not be construed as sales or marketing material or an offer of solicitation for the purchase or sale of, any financial instrument, product or service sponsored by AllianceBernstein or its affiliates.

To Hong Kong Readers: The issuer of this document is AllianceBernstein Hong Kong Limited (聯博香港有限公司). This document has not been reviewed by the Securities and Futures Commission in Hong Kong.

© 2022 AllianceBernstein L.P.. The [A/B] logo is a service mark of AllianceBernstein and AllianceBernstein® is a registered trademark used by permission of the owner, AllianceBernstein L.P.

